Skip to main content
. 2023 Dec 14;130(3):425–433. doi: 10.1038/s41416-023-02528-z

Fig. 2.

Fig. 2

Kaplan–Meier Curve for progression free survival (PFS) in (a) CPLD (carboplatin/pegylated liposomal doxorubicin) and (b) CP (carboplatin/paclitaxel) arms. PFS progression free survival, CPLD carboplatin/pegylated liposomal doxorubicin, CP carboplatin/paclitaxel; CA-125 PD, CA-125 progression; RECIST PD, RECIST progression. y-axis – proportion alive, x-axis – progression time in months.